Halbert Hargrove Global Advisors LLC Sells 3,544 Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Halbert Hargrove Global Advisors LLC reduced its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 42.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,846 shares of the company’s stock after selling 3,544 shares during the quarter. Halbert Hargrove Global Advisors LLC owned about 0.08% of Global X Genomics & Biotechnology ETF worth $39,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. SBI Securities Co. Ltd. bought a new stake in shares of Global X Genomics & Biotechnology ETF during the fourth quarter valued at approximately $50,000. Sanctuary Advisors LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the fourth quarter valued at approximately $104,000. Sei Investments Co. bought a new stake in shares of Global X Genomics & Biotechnology ETF during the fourth quarter valued at approximately $114,000. Oxinas Partners Wealth Management LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 35.9% during the first quarter. Oxinas Partners Wealth Management LLC now owns 14,461 shares of the company’s stock valued at $115,000 after purchasing an additional 3,818 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 11.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 12,604 shares of the company’s stock valued at $122,000 after purchasing an additional 1,265 shares during the last quarter. 56.95% of the stock is owned by institutional investors.

Global X Genomics & Biotechnology ETF Price Performance

GNOM opened at $8.24 on Tuesday. Global X Genomics & Biotechnology ETF has a one year low of $6.80 and a one year high of $11.88. The company’s 50 day simple moving average is $7.88 and its 200-day simple moving average is $8.95. The stock has a market capitalization of $49.93 million, a P/E ratio of -3.52 and a beta of 1.03.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.